Latest market price
16.10
-0.68-4.05%
OverviewShort InterestFilings
RAREQT29Ultragenyx Pharmaceutical Inc.·NASDAQ
16.10-4.05%
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
TRAX-0.33%$45.08NVAX-3.72%$10.08NUVB-0.21%$4.76KLRA-4.10%$12.86REPL+1.27%$17.61STOK-0.23%$26.29QURE-1.86%$24.83NTLA-5.74%$12.47
Snapshot
Index—P/E—EPS (ttm)-5.84Insider Own4.08%Shs Outstand98.59MPerf Week2.88%
Market Cap1.59BForward P/E—EPS next Y-0.65Insider Trans-0.86%Shs Float90.20MPerf Month9.15%
Enterprise Value2.50BPEG—EPS next Q-1.10Short Float22.34%Perf Quarter-35.65%
Income-586.00MP/S2.21EPS this Y—Short Ratio4.95Perf Half Y-35.00%
Sales717.00MP/B—EPS next Y—ROA-46.39%Short Interest20.15MPerf YTD-30.00%
Book/sh-2.88P/C5.44EPS next 5Y—ROE—52W High39.89 -59.64%Perf Year-53.45%
Cash/sh2.96P/FCF—EPS past 3/5Y—ROIC-53.48%52W Low12.73 26.47%Perf 3Y-50.96%
Dividend Est.—EV/EBITDA—Sales past 3/5Y22.85% 19.95%Gross Margin83.12%Volatility5.47% 4.84%Perf 5Y-79.42%
Dividend TTM—EV/Sales3.48EPS Y/Y TTM—Oper. Margin-73.77%ATR (14)0.85Perf 10Y-75.83%
Dividend Ex-Date—Quick Ratio1.56Sales Y/Y TTM17.73%Profit Margin-81.79%RSI (14)49.82Recom2.38
Dividend Gr. 3/5Y—Current Ratio1.73EPS Q/Q23.08%SMA203.55%Beta0.34Target Price25.46
Payout0.00%Debt/Eq—Sales Q/Q28.92%SMA50-5.36%Rel Volume0.55Prev Close16.78
Employees1,371LT Debt/Eq—EarningsNov 03SMA200-29.68%Avg Volume4.25MPrice16.10
IPO DateJan 31, 2014Option/ShortYes / YesEPS/Sales Surpr.26.09% 16.89%Net Debt/EBITDA—Volume2,333,527Change-4.05%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-14-26InitiatedUBSNeutral$73 → $16
Sep-21-26ReiteratedEvercore ISI GroupIn Line$16 → $18
Sep-21-26ReiteratedBarclaysOverweight$32 → $35
Sep-18-26ReiteratedCantor FitzgeraldOverweight$33 → $39
Sep-18-26ReiteratedCanaccord GenuityBuy$37 → $39
Sep-18-26ReiteratedMorgan StanleyEqual Weight$18 → $20
Sep-04-26ReiteratedBarclaysOverweight$43 → $32
Sep-03-26ReiteratedMorgan StanleyOverweight$74 → $18
Sep-03-26ReiteratedRBC CapitalOutperform$40 → $19
Sep-03-26ReiteratedRobert W. Baird$40 → $16
Latest News· Times ET
Oct-28-26
Oct-28-2609:00AM
Analysts Estimate Cytek Biosciences, Inc. (CTKB) to Report a Decline in Earnings: What to Look Out forYahoo
Oct-27-26
Oct-27-2604:05PM
Ultragenyx to Host Conference Call for Third Quarter 2026 Financial Results and Corporate Updateglobenewswire.com
04:00PM
AMGEN TO PRESENT NEW DATA ACROSS RARE AND OTHER SERIOUS AUTOIMMUNE DISEASES AT ACR CONVERGENCE 2026prnewswire.com
11:06AM
Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q3 Releasezacks.com
Oct-20-26
Oct-20-2604:22AM
Ultragenyx Pharmaceutical (NASDAQ:RARE) CFO Howard Horn Sells 7,066 Shares of Company Stockdefenseworld.net
Oct-19-26
Oct-19-2601:52PM
Sector Update: Healthcare Stocks Softer Monday AfternoonYahoo
Oct-15-26
Oct-15-2601:31PM
UBS Initiates Coverage On Ultragenyx Pharmaceutical with Neutral Rating, Announces Price Target of $16Benzinga
11:35AM
RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Weekzacks.com
Oct-14-26
Oct-14-2611:31AM
Can RARE's Approved Product Portfolio Drive Its Next Growth Phase?zacks.com
08:30AM
Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $203 Millionglobenewswire.com
04:11AM
Rep. Gilbert Ray Cisneros, Jr. Acquires Shares of Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:TSM)defenseworld.net
Oct-12-26
Oct-12-2601:44AM
Analyzing Atara Biotherapeutics (NASDAQ:ATRA) & Ultragenyx Pharmaceutical (NASDAQ:RARE)defenseworld.net
Oct-09-26
Oct-09-2611:18AM
FDA review docs spark Revolution sell-off; Zealand diabetes data underwhelm analystsYahoo
Oct-08-26
Oct-08-2611:50AM
Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cashzacks.com
Oct-07-26
Oct-07-2612:49PM
Ultragenyx shares rise after agreeing to sell FDA priority review voucher for $210 millionproactiveinvestors.com
Company

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international markets. The company's portfolio of marketed biologic products addresses several serious diseases. This includes Crysvita (burosumab), an antibody that targets fibroblast growth factor 23, used to treat X-linked hypophosphatemia and tumor-induced osteomalacia. Mepsevii offers enzyme replacement therapy for both pediatric and adult patients suffering from Mucopolysaccharidosis VII. Dojolvi is available for individuals with long-chain fatty acid oxidation disorders, while Evkeeza (evinacumab) provides a treatment option for homozygous familial hypercholesterolemia. Ultragenyx also boasts a robust pipeline of investigational therapies. Notable candidates include DTX401, an adeno-associated virus 8 (AAV8) gene therapy for glycogen storage disease type Ia, and DTX301, another AAV8 gene therapy aimed at ornithine transcarbamylase deficiency. Other promising developments feature UX143, a human monoclonal antibody for osteogenesis imperfecta; GTX-102, an antisense oligonucleotide designed for Angelman syndrome; UX701, targeting Wilson disease; and UX053, in development for glycogen storage disease type III. To advance its research and development efforts, Ultragenyx Pharmaceutical Inc. maintains strategic collaboration and licensing agreements with numerous partners, such as Kyowa Kirin Co., Ltd., Saint Louis University, REGENXBIO Inc., Bayer Healthcare LLC, GeneTx, Mereo, University of Pennsylvania, Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc., and Daiichi Sankyo Co., Ltd. The company was founded in 2010 and operates from its headquarters in Novato, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue717673560434—————
Cost of Goods Sold Incl. D&A1211097745—————
Gross Profit596564484389—————
Selling, General and Administrative Excl. Other352349322310—————
Research and Development773750698648—————
Other Operating Expense00-10—————
Operating Income-529-535-536-569—————
Interest Expense76626366—————
Unusual Expense
—————————
Non-Operating Income (Expense)22263127—————
Net Income Before Taxes-583-571-568-608—————
Income Taxes442-2—————
Consolidated Net Income-586-575-569-607—————
Net Income From Continuing Operations-586-575-569-607—————
Net Income-586-575-569-607—————
EPS (Recurring)-5.84-5.83-6.29-8.25—————
EPS (Basic, Before Extraordinaries)-5.84-5.83-6.29-8.25—————
EPS (Diluted)-5.84-5.83-6.29-8.25—————
EBITDA-473-474-469-516—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio2.293.386.848.15—————
Gross Margin83.1283.8086.4389.63—————
Operating Margin-73.78-79.49-95.71-131.11—————
Net Margin-81.73-85.44-101.61-139.86—————
Shares Outstanding102999174—————
Market Capitalization1,6422,2773,8283,539—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$40.09$32.40$24.71$17.02$9.33● Close Price0.00M0.63M1.26M1.90M2.53MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Horn HowardChief Financial OfficerOct 15 '26Sale15.277,066107,89889,229Oct 19
Huizenga Theodore AlanSVP, Chief Accounting OfficerSep 15 '26Sale13.571,28317,41067,863Sep 15
Huizenga Theodore AlanSVP, Chief Accounting OfficerSep 03 '26Sale13.991612,25269,146Sep 08
Parschauer Karah HerdmanEVP and Chief Legal OfficerAug 03 '26Sale24.921,90047,34892,562Aug 04
Horn HowardChief Financial OfficerAug 03 '26Sale24.924,696117,02496,295Aug 04
Horn HowardChief Financial OfficerJul 01 '26Sale33.134,698155,645100,991Jul 06
Sanders Corazon (Corsee) D.DirectorJun 15 '26Sale25.052,00050,10021,095Jun 15
Parschauer Karah HerdmanEVP and Chief Legal OfficerJun 15 '26Sale24.621,89946,75394,462Jun 15
Horn HowardChief Financial OfficerJun 01 '26Sale23.774,653110,602105,689Jun 01
SULIMAN SHEHNAAZDirectorMay 18 '26Sale25.125,740144,18927,951May 18
Crombez EricEVP and Chief Medical OfficerMay 05 '26Sale24.963448,586111,189May 06
Horn HowardChief Financial OfficerMay 01 '26Sale24.904,683116,607110,342May 04
Horn HowardChief Financial OfficerApr 01 '26Sale20.974,68398,20380,351Apr 02
Parschauer Karah HerdmanEVP and Chief Legal OfficerMar 10 '26Sale22.673,50879,52666,820Mar 10
Parschauer Karah HerdmanEVP and Chief Legal OfficerMar 06 '26Sale21.406,018128,78570,328Mar 10
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.